Valuation: Shield Therapeutics plc

Market Cap 51.89M 68.71M 60.29M 56.94M 97.14M 6.59B 97.83M 681M 264M 3.36B 258M 252M 10.81B P/E 2026 *
323x
P/E 2027 * 6.54x
Enterprise Value 70.34M 93.14M 81.73M 77.19M 132M 8.93B 133M 924M 358M 4.56B 350M 342M 14.66B EV / Sales 2026 *
1.32x
EV / Sales 2027 * 1x
Free-Float
38.25%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Shield Therapeutics plc

1 day+7.22%
1 week+10.64%
Current month-14.75%
1 month+7.22%
3 months-14.75%
6 months-36.59%
Current year-47.21%
1 week 4.6
Extreme 4.6
5.37
1 month 4.4
Extreme 4.4
6.4
Current year 3.7
Extreme 3.7
12.5
1 year 3.7
Extreme 3.7
12.5
3 years 1.06
Extreme 1.0625
12.85
5 years 1.06
Extreme 1.0625
52
10 years 1.06
Extreme 1.0625
202
Manager TitleAgeSince
Chief Executive Officer 64 24/07/2024
Director of Finance/CFO 50 01/09/2026
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 68 01/02/2016
Chairman 70 18/06/2020
Director/Board Member 59 26/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
14/10/25 Free

Chief Executive Officer

1,547,262 0.1485%
13/02/25 Free

Chief Executive Officer

5,000,000 0.4800%
13/02/25 Buy

Chief Executive Officer

575,000 0.0552%
Change 5-day change 1-year change 3-year change Capi.($)
+7.22%+10.64%-29.35%-58.40% 68.59M
-1.11%+0.43%+41.89%-5.56% 79.49B
+1.69%+28.87%+706.62%+102.21% 77.78B
-1.21%-0.34%-10.33%-29.82% 60.16B
-1.80%-2.15%-15.06%+26.38% 46.14B
+1.18%+3.03%+9.11%+169.01% 45.93B
-0.02%+4.79%+66.45%-11.45% 33.45B
-0.14%-0.93%+52.02%+111.30% 25.22B
-0.10%+3.69%+4.89%+166.22% 22.15B
+0.05%-2.42%+57.59%+97.38% 15.25B
Average +0.58%+3.00%+88.38%+56.73% 40.56B
Weighted average by Cap. -0.14%+4.93%+152.63%+54.93%

Financials

2026 *2027 *
Net sales 53.48M 70.81M 62.14M 58.69M 100M 6.79B 101M 702M 272M 3.47B 266M 260M 11.14B 69.92M 92.57M 81.23M 76.72M 131M 8.87B 132M 918M 356M 4.53B 348M 340M 14.57B
Net income 258K 342K 300K 283K 483K 32.74M 486K 3.39M 1.31M 16.73M 1.28M 1.25M 53.76M 7.74M 10.25M 9M 8.5M 14.5M 983M 14.6M 102M 39.38M 502M 38.5M 37.66M 1.61B
Net Debt 18.45M 24.43M 21.44M 20.25M 34.54M 2.34B 34.79M 242M 93.85M 1.2B 91.73M 89.75M 3.84B 18M 23.83M 20.91M 19.75M 33.69M 2.28B 33.93M 236M 91.53M 1.17B 89.47M 87.54M 3.75B
Logo Shield Therapeutics plc
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
Employees
61
Date Price Change Volume
25/09/26 GBX 5.200 +7.22% 6,728,147
24/09/26 GBX 4.850 0.00% 2,396,248
23/09/26 GBX 4.850 +2.11% 3,055,597
22/09/26 GBX 4.750 0.00% 728,393
21/09/26 GBX 4.750 +1.06% 594,145
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0485GBP
Average target price
0.1667GBP
Spread / Average Target
+243.65%

Annual profits - Rate of surprise